What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Nicotinamide adenine dinucleotide
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing NAD+ inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
NAD+ (Nicotinamide Adenine Dinucleotide, oxidized form) is a fundamental coenzyme involved in cellular redox reactions, sirtuin-mediated deacetylation, PARP-mediated DNA damage response, and CD38-mediated calcium signaling. NAD+ levels decline with age across mammalian tissues, and the restoration or boosting of NAD+ is the central thesis of the contemporary longevity-research field, driving extensive interest in NAD+ precursors (NMN, NR) and direct-IV NAD+ supplementation in both research and med-spa contexts. NAD+ is not a peptide but is included in the catalog because of its frequent co-administration alongside peptide research products and its established role in cellular-energy-metabolism workflows. PeptideXpo supplies NAD+ at ≥99.0% HPLC purity in lyophilized form. The large fill sizes (100, 500, 1000 mg) reflect the gram-scale dosing typical for IV-infusion preparations and med-spa workflows rather than the μg-mg scales of peptide research products. The analytical packet covers RP-HPLC, UV-Vis absorbance at 260 nm (the diagnostic adenine wavelength), and residual-solvent profiling. Storage at -20 °C protected from light extends the lyophilized shelf life; once reconstituted, NAD+ solutions should be used promptly because the molecule is moisture- and oxidation-sensitive in solution.
Who buys this, and why
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Primary buyer fit: 503A / 503B compounding pharmacies, medical aesthetic clinics and med spas, and academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Sold as a bulk active for research and for compounding-pharmacy formulation in jurisdictions where local regulations permit. Not a finished dosage form and not labeled for direct human administration as shipped. The GLP-1 class is on active regulatory watchlists in several major markets, buyers are responsible for verifying current scheduling and compounding eligibility for the destination at the time of dispense.
Frequently asked questions
NAD+ is not a peptide, it is a dinucleotide coenzyme consisting of nicotinamide mononucleotide linked to adenosine monophosphate through a pyrophosphate bridge. We include it in the catalog because NAD+ is frequently co-administered alongside peptide research products in longevity-research and med-spa workflows. The handling differs from peptides in two main ways: (1) the analytical methods are HPLC plus UV-Vis at 260 nm (the adenine absorbance) rather than the peptide-focused HPLC + mass spec + sequence verification, and (2) NAD+ in solution is more sensitive to moisture-driven hydrolysis than lyophilized peptides, so reconstituted solutions should be used promptly rather than stored as working stocks.
All three feed into the same NAD+ salvage pathway but at different entry points. NMN (Nicotinamide Mononucleotide) is the immediate biosynthetic precursor to NAD+; NR (Nicotinamide Riboside) is converted to NMN and then to NAD+; direct NAD+ supplementation bypasses both precursor steps. The trade-off across the three is dosing convenience versus bioavailability: oral NR has the best oral bioavailability; oral NMN is somewhat poorer but commercially established; direct IV NAD+ has the most rapid systemic effect but requires injection. The choice for research depends on which level of the salvage pathway the experimental question targets.
NAD+ is dosed at gram-scale rather than the μg-mg scale typical of peptide therapeutics. A standard IV-infusion protocol delivers 250-1000 mg of NAD+ per session, sometimes higher in extended-infusion protocols. The large fill sizes (500 mg, 1000 mg lyophilized) reflect this clinical use case and minimize the number of vials needed per infusion preparation. Med-spa providers typically reconstitute one fill into a saline IV bag for the procedure. Research-lab buyers using NAD+ in cell-culture or biochemical-assay work can use a fraction of the 100 mg fill and store the remainder sealed under nitrogen at -20 °C.
